Today’s Market Runner: Mylan NV Sets Yearly Low; Strong Momentum for Sellers

Today's Market Runner: Mylan NV Sets Yearly Low; Strong Momentum for Sellers

The stock of Mylan NV (NASDAQ:MYL) hit a new 52-week low and has $31.82 target or 6.00% below today’s $33.85 share price. The 5 months bearish chart indicates high risk for the $18.11 billion company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $31.82 price target is reached, the company will be worth $1.09 billion less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 9.87M shares traded hands or 35.21% up from the average. Mylan NV (NASDAQ:MYL) has declined 22.80% since April 1, 2016 and is downtrending. It has underperformed by 24.01% the S&P500.

Analysts await Mylan NV (NASDAQ:MYL) to report earnings on November, 4. They expect $1.60 earnings per share, up 11.89% or $0.17 from last year’s $1.43 per share. MYL’s profit will be $856.01M for 5.29 P/E if the $1.60 EPS becomes a reality. After $1.16 actual earnings per share reported by Mylan NV for the previous quarter, Wall Street now forecasts 37.93% EPS growth.

Mylan NV (NASDAQ:MYL) Ratings Coverage

Out of 16 analysts covering Mylan Inc. (NASDAQ:MYL), 10 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 63% are positive. $85 is the highest target while $46 is the lowest. The $59.80 average target is 76.66% above today’s ($33.85) stock price. Mylan Inc. has been the topic of 27 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Leerink Swann maintained Mylan NV (NASDAQ:MYL) on Monday, August 15 with “Outperform” rating. The firm earned “Equal-Weight” rating on Thursday, December 3 by Morgan Stanley. The rating was initiated by Mizuho with “Buy” on Wednesday, October 26. The firm has “Buy” rating by Deutsche Bank given on Friday, August 7. The firm has “Strong Buy” rating given on Monday, October 10 by Raymond James. As per Wednesday, November 18, the company rating was reinitiated by JP Morgan. The stock has “Outperform” rating given by Leerink Swann on Wednesday, May 4. The firm has “Buy” rating by Deutsche Bank given on Tuesday, July 28. The rating was maintained by BTIG Research on Wednesday, August 19 with “Buy”. The company was upgraded on Thursday, August 27 by Zacks.

According to Zacks Investment Research, “Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.”

Insitutional Activity: The institutional sentiment decreased to 0.45 in 2016 Q2. Its down 0.05, from 0.5 in 2016Q1. The ratio is negative, as 6 funds sold all Mylan NV shares owned while 5 reduced positions. 1 funds bought stakes while 4 increased positions. They now own 533,685 shares or 37.96% less from 860,251 shares in 2016Q1.
Eagle Asset Mgmt holds 56,209 shares or 0.02% of its portfolio. Amer, a Massachusetts-based fund reported 1,600 shares. Ntv Asset Mgmt Limited Company reported 15,990 shares or 0.26% of all its holdings. Westport Resource Management holds 26,765 shares or 0.37% of its portfolio. Jacobs Ca reported 7,305 shares or 0.07% of all its holdings. Gemmer Asset Mgmt Ltd Co last reported 0% of its portfolio in the stock. Covington Cap Management reported 39,339 shares or 0.16% of all its holdings. Gulf National Bank & Trust (Uk) Limited holds 0.09% of its portfolio in Mylan NV (NASDAQ:MYL) for 123,183 shares. Vantage Invest Advsrs Ltd Company reported 712 shares or 0.01% of all its holdings. Princeton Portfolio Strategies Gp accumulated 135,477 shares or 1.89% of the stock. Novare Mngmt Ltd Liability Corporation holds 0.93% or 79,851 shares in its portfolio. Icon Advisers Com accumulated 0.1% or 35,000 shares.

More notable recent Mylan NV (NASDAQ:MYL) news were published by: Globenewswire.com which released: “MYLAN N.V. INVESTOR ALERT: Hagens Berman Reminds Investors in Mylan N.V …” on November 03, 2016, also Investorplace.com with their article: “Mylan NV (MYL) Stock Holders Can Shrug Off Kaleo’s EpiPen Threat” published on October 27, 2016, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 06, 2016. More interesting news about Mylan NV (NASDAQ:MYL) were released by: Investorplace.com and their article: “Why Alphabet Inc (GOOG), Mylan NV (MYL) And Tesaro Inc (TSRO) Are 3 of Today’s …” published on October 10, 2016 as well as Investorplace.com‘s news article titled: “3 Stocks to Watch Monday: Mylan NV (MYL), Bristol-Myers Squibb Co (BMY) and …” with publication date: October 10, 2016.

MYL Company Profile

Mylan N.V., incorporated on July 7, 2014, is a global pharmaceutical company. The Firm develops, licenses, makes, markets and distributes generic, branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). The Firm operates through two divisions: Generics and Specialty. The principal markets for Generics are pharmaceutical wholesalers and distributors; group purchasing organizations; drug store chains; independent pharmacies; drug manufacturers; institutions, and public and governmental agencies primarily within the United States and Canada (collectively, North America); Europe, and India, Australia, Japan, New Zealand and Brazil (collectively, Rest of World). The Generics segment also focuses on developing API with non-infringing processes for both internal use and to partner with manufacturers in regulated markets, such as the United States and the European Union at market formation. The principal market for Specialty is pharmaceutical wholesalers and distributors, pharmacies and healthcare institutions primarily in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment